Conditional Approval and Pricing of New Drugs – Asrar Qureshi’s Blog Post #1313

Asrar Qureshi’s blog delves into the complex journey of health innovations from discovery to patient access, highlighting the significant costs and time involved in drug development. It emphasizes the need for a collaborative approach between pharmaceutical companies and governments to address pricing, making life-saving medications accessible while managing risks and uncertainties effectively.
Share
View Post

AI and Machine Learning in Pharmaceutical Drug Development – Asrar Qureshi’s Blog Post #1102

The blog post by Asrar Qureshi discusses the transformative impact of Artificial Intelligence (AI) and Machine Learning (ML) on the pharmaceutical industry. It highlights innovations in drug discovery, preclinical development, clinical trials, and manufacturing, emphasizing efficiency and personalized medicine. However, challenges like data privacy and regulatory uncertainty must be addressed.
Share
View Post

New Drug Modalities – Asrar Qureshi’s Blog Post 1047

Asrar Qureshi’s blog discusses the Boston Consulting Group’s second annual report on the growth of new drug modalities. It highlights advancements in antibodies, recombinant products, cell therapies, gene therapies, and mRNA applications, emphasizing their implications for biopharma companies and patient care. The future of these modalities depends on their unique benefits and market speed.
Share